Attached files
| file | filename |
|---|---|
| 10-K - FORM 10-K - Checkpoint Therapeutics, Inc. | tmb-20201230x10k.htm |
| EX-32.2 - EXHIBIT 32.2 - Checkpoint Therapeutics, Inc. | tmb-20201230xex32d2.htm |
| EX-32.1 - EXHIBIT 32.1 - Checkpoint Therapeutics, Inc. | tmb-20201230xex32d1.htm |
| EX-31.2 - EXHIBIT 31.2 - Checkpoint Therapeutics, Inc. | tmb-20201230xex31d2.htm |
| EX-31.1 - EXHIBIT 31.1 - Checkpoint Therapeutics, Inc. | tmb-20201230xex31d1.htm |
| EX-4.3 - EXHIBIT 4.3 - Checkpoint Therapeutics, Inc. | tmb-20201230xex4d3.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
Checkpoint Therapeutics, Inc.
New York, New York
We hereby consent to the incorporation by reference in the Registration Statements on Form S3 (No. 333-251005) and Form S-8 (No. 333-216856, No. 333-221488 and No. 333-251000) of Checkpoint Therapeutics, Inc. of our report dated March 12, 2021, relating to the financial statements which appears in this Annual Report on Form 10-K.
/s/ BDO USA, LLP |
| |
| | |
New York, New York | | |
| | |
March 12, 2021 | | |